51670 Federal Register / Vol. 62, No. 191 / Thursday, October 2, 1997 / Notices

burden; (3) ways to enhance the quality,

utility, and clarity of the information to

be collected; and (4) the use of

automated collection techniques or

other forms of information technology to

minimize the information collection

burden.

Type of Information Collection

Request: Extension of a currently

approved collection; Title of

Information Collection: ESRD

Beneficiary Selection and Supporting

Regulations Contained in 42 CFR

414.330; Form No.: HCFA–382 (OMB#

0938–0372); Use: ESRD facilities have

each new home dialysis patient select

one of two methods to handle Medicare

reimbursement. The intermediaries pay

for the beneficiaries selecting Method I

and the carriers pay for the beneficiaries

selecting Method II. This system was

developed to avoid duplicate billing by

both intermediaries and carriers.

Frequency: Other (One time only);

Affected Public: Individuals or

Households, Business or other for-profit,

and Not-for-profit institutions; Number

of Respondents: 3,100; Total Annual

Responses: 3,100; Total Annual Hours:

259.

To obtain copies of the supporting

statement and any related forms for the

proposed paperwork collections

referenced above, E-mail your request,

including your address and phone

number, to Paperwork@hcfa.gov, or call

the Reports Clearance Office on (410)

786–1326. Written comments and

recommendations for the proposed

information collections must be mailed

within 30 days of this notice directly to

the OMB desk officer: OMB Human

Resources and Housing Branch,

Attention: Allison Eydt, New Executive

Office Building, Room 10235,

Washington, D.C. 20503.

Dated: September 24, 1997.

John P. Burke III,

HCFA Reports Clearance Officer, HCFA Office

of Information Services, Information

Technology Investment Management Group,

Division of HCFA Enterprise Standards.

[FR Doc. 97–26158 Filed 10–1–97; 8:45 am]

BILLING CODE 4120–03–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

HHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the United States in

accordance with 35 U.S.C. 207 to

achieve expeditious commercialization

of results of federally funded research

and development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for U.S. companies and may also be

available for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 24, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220: A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

Genes for Niemann-Pick Type C

Disease

DA Tagle, ED Carstea, JA Morris, PG

Pentchev, WJ Pavan, MA Rosenfeld,

SK Loftus (NINDS/NHGRI)

Serial No. 60/051,682 filed 03 Jul 97

Licensing Contact: Leopold J. Luberecki,

Jr., 301/496–7735 ext. 223

Niemann-Pick disease is a class of

inherited lipid storage diseases.

Niemann-Pick Type C disease is an

autosomal recessive neurovisceral lipid

storage disorder which leads to systemic

and neurological abnormalities

including ataxia, seizures, and loss of

speech. Patients with the disease

typically die as children. The

biochemical hallmark of Niemann-Pick

Type C cells is the abnormal

accumulation of unesterified cholesterol

in lysosomes, which results in the

delayed homeostatic regulation of both

uptake and esterification of low density

lipoprotein (LDL) cholesterol. NiemannPick Type C is characterized by

phenotypic variability. The disease

appears at random in families that have

no history of the disorder, making

diagnosis problematic. This invention

provides the human gene for NiemannPick Type C disease and the nucleic

acid sequences corresponding to the

human gene for Niemann-Pick Type C

disease. Also provided is the mouse

homolog of the human gene. The

invention could lead to improved

diagnosis and the design of therapies for

the disease and improved means of

detection of carriers of the gene. In

addition, this invention may contribute

to the understanding and development

of treatments for atherosclerosis, a more

common disorder associated with

cholesterol buildup that involves the

accumulation of fatty tissue inside

arteries that blocks blood flow, leading

to heart disease and stroke. The

invention may also lead to additional

discoveries concerning how cholesterol

is processed in the body.

AIB–1, A Steroid Receptor Co-Activator

Amplified in Breast and Ovarian

Cancer

PS Meltzer, JM Trent (NHGRI)

OTT Reference No. E–018–97/0 filed 17

Jun 97

Licensing Contact: Ken Hemby, 301/

496–7735 ext. 265

Breast cancer is the number one

cancer in U.S. women, with over

185,000 cases in 1996 and an estimated

44,560 deaths in the past year. Breast

cancer arises from estrogen-responsive

breast epithelial cells. Estrogen activity

is though to promote the development

of breast cancer, and many breast

cancers are initially dependent on

estrogen at the time of diagnosis. Antiestrogen compositions have therefore

been used to threat breast cancer.

AIB–1 (Amplified in Breast Cancer–1)

is a novel gene that is pivotal to a

crucial metabolic pathway linked to the

growth and progression of human breast

cancer. In many cancers, especially

breast cancer, tumor cells have

amplified copies of genes that can give

the cancer a growth advantage. AIB–1,

located on the long arm of chromosome

20, is one such amplified gene. Highlevel AIB–1 amplification and

overexpression have been observed in

several estrogen receptor (ER) positive

breast and ovarian cancer cell lines, as

well as in uncultured breast cancer

specimens. AIB–1 has also been found

to be expressed in prostate epithelial

cells.

AIB–1 is the most recently identified

member of a gene family known as

SRC–1 (steroid receptor coactivator), all

of which interact with genes for steroid

hormone receptors, ultimately

enhancing tumor cell growth.

This invention provides the gene for

AIB–1, a novel steroid receptor coactivator which is overexpressed in

breast cancer cells. It also encompasses

diagnostic assays for steroid hormoneresponsive cancers and screening assays

to identify compounds which inhibit

interactions of the co-activator with

steroid hormone receptors and other

proteins in this pathway.

Methods and Compositions for

Inhibiting Inflammation and

Angiogenesis

K Kelly (NCI)

Serial No. 60/027,871 filed 25 Oct 96
Federal Register / Vol. 62, No. 191 / Thursday, October 2, 1997 / Notices 51671

Licensing Contact: J. Peter Kim, 301/

496–7056 ext. 264

The invention provides compositions

and methods directed to isolated α

subunits of the 7TM protein CD97.

CD97 is a heterodimer existing in three

isoforms, namely three forms of α

subunit and one invariant β subunit.

The invention provides compositions

and methods for detecting a subunit of

CD97, a T-cell protein which is

unregulated in activated T-cells and is

involved in the onset and maintenance

of inflammation and angiogenesis. The

invention provides an isolated protein

comprising a soluble CD97 α subunit,

and an isolated nucleic acid encoding a

soluble Cd97 α subunit protein. The

invention also provides methods for

identifying compounds which inhibit

soluble CD97 α subunit expression. The

invention may be used to inhibit

angiogenesis associated with chronic

inflammation in a mammal by

administering a therapeutically effective

amount of a CD97 antagonist. Another

application includes determining the

degree of inflammation at a site in a

mammal with an antibody composition

specifically reactive to a soluble CD97 α

subunit. Further, it should be noted that

these compositions and methods further

have in vitro utility in the construction

of proteins and subsequences thereof for

the construction of antibodies, and

nucleic acids and subsequences thereof

for use as probes.

Peptides With Laminin Activity

Y Yamada, JO Graf, Y Iwamoto, F

Robey, HK Kleinman,

M Sasaki, GR Martin (NIDR)

U.S. Patent 5,092,885 issued 03 Mar 92

Licensing Contact: Jaconda Wagner,

301/496–7735, ext. 284

Peptides with laminin activity,

including YIGSR, are claimed. These

peptides block angiogenesis, alter the

formation of capillary structures by

endothelial cells, prevent the formation

of excess blood vessels in tissue and

inhibit in vivo tumor cell colonization

of tissues. These peptides can be used,

among other things, to inhibit

metastasis.

This research has been described in

B.J. Cancer 73:589, 1996; Cancer Res

54:5005, 1994; Semin Cancer Biol 1993

Aug; 4(4):259–65; Cancer Res 1993 Aug

1;53(15):3459–61; Cell 1987 Mar

27;48(6):989–9.

Laminin A Peptides

Y Yamada, HK Kleiman, M Sasaki, GR

Martin (NIDR)

U.S. Patent 5,211,657 issued 18 May 93

Licensing Contact: Jaconda Wagner,

301/496–7735, ext. 284

This invention relates to peptides and

derivatives thereof having laminin-like

activity, as well as a pharmaceutical

composition of the peptide. The

peptides claimed include SerineIsoleucine-Lysine-Valine-AlanineValine (SIKVAV). Methods for

promoting increased adhesion and

migration of epithelial cells is also

disclosed. The peptides have wide

usage in research, nerve regeneration

and cancer treatment. For example, this

invention may be useful as an adhesion

and regeneration agent for nerve guides

and as an adhesion agent for vascular

prothesis.

This research had been described in

Bioorganic Medinal Chem Lett 5:711,

1995; J Neurosci Res 1995 Oct

15;42(3):314–22; Cancer Res 1995 Jun

1;55(11):2476–80; FEBS Lett 1995 May

29;365(2–3):227–3; J Cell Physiol 1994

Jul;160(1):185–93; Cell Immunol 1994

Jan; 153(1):94–104.

Dated: September 25, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–26171 Filed 10–1–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following meeting

of the National Cancer Institute Special

Emphasis Panel (SEP) meeting:

Name of SEP: Efficacy Studies of

Chemopreventive Agents in animal Models

and Evaluation of Chemopreventive Agents

by in Vivo Screening Assays.

Date: October 20–21, 1997.

Time: 8:30 a.m. to 5:00 p.m.

Place: Double Tree Hotel—Rockville, 1750

Rockville Pike, Rockville, MD 20852.

Contact Person: Courtney M. Kerwin,

Ph.D., M.P.H., Scientific Review

Administrator, National Cancer Institute,

NIH, Executive Plaza North, Room 630I, 6130

Executive Boulevard, MSC 7405, Bethesda,

MD 20892–7405, Telephone: 301/496–7421.

Purpose/Agenda To review and evaluate

proposals submitted in response to master

agreement announcements.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Proposals and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material and

personal information concerning individuals

associated with the proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control.)

Dated: September 26, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–26167 Filed 10–1–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and

Human Development; Notice of Closed

Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 United States Code

Appendix 2), notice is hereby given of

the following National Institute of Child

Health and Human Development

Special Emphasis Panel (SEP) meeting:

Name of SEP: Duration of Labor and

Cesarean Delivery in Association With

Epidural Analgesia in Nullipara

(Teleconference).

Date: September 30, 1997.

Time: 11:00 a.m. (ET)—adjournment.

Place: 6100 Executive Boulevard, 6100

Building—Room 5E01, Rockville, Maryland

20852.

Contact Person: Hameed Khan, Ph.D.,

Scientific Review Administrator, NICHD,

6100 Executive Boulevard, 6100 Building—

Room 5E01, Rockville, Maryland 20852,

Telephone: 301–496–1696.

Purpose/Agenda: To provide concept

review of proposed contract solicitations.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(9)(B), Title 5 U.S.C. The discussions

could reveal the specific details of future

requests for contract proposals (RFPs), the

disclosure of which would significantly

frustrate implementation of the agency’s

proposed contract activities by giving unfair

competitive advantage to private firms or

individuals.

This notice is published less than 15 days

prior to the meeting due to the urgent need

to meet timing limitations imposed by the

review and funding cycle.

(Catalog of Federal Domestic Assistance

Program Nos. [93.864, Population Research

and No. 93.865, Research Mothers and

Children], National Institutes of Health)

Dated: September 25, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–26099 Filed 10–1–97; 8:45 am]

BILLING CODE 4140–01–M